NOVACYT SIGNS $3.0M DIAGNOSTICS SUPPLY AGREEMENT WITH GENESIS DIAGNOSTICS

PrimerDesign Genesis Diagnostics ENG Paris, France and Camberley, UK – 27th November 2018 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, today announces its molecular testing division, Primerdesign Ltd. (Primerdesign), has signed an exclusive supply agreement worth a minimum of $3 million with Genesis Diagnostics, a US-based full service diagnostic

Visit Page

NOVACYT HALF YEAR 2018 RESULTS Molecular product revenues up 18% to €3m Gross margin increases to 64%

Novacyt half year 2018 results Paris, France and Camberley, UK – 26 September 2018 – Novacyt (ALTERNEXT: ALNOV; AIM: NCYT), an international specialist in clinical diagnostic products, today announces unaudited financial results for the six months ended 30 June 2018.

Visit Page